Table 1.
Principal small molecules | Target molecule | Stage of development | Reference |
---|---|---|---|
Etidronate, Clodronate | ATP‐requiring molecules | Marketed | ( 9 ) |
Alendronate, Zoledronate | FPP synthase | Marketed | ( 9 ) |
MK‐0822, AAE581 | Cathepsin K | Clinical | ( 12 ) |
AZD0530, CGP76030 | c‐Src | Clinical, Preclinical | ( 19 ) |
L‐000845704, SB265123 | αVβ3 integrin | Clinical, Preclinical | ( 23, 57 ) |
FR202126, Iejimalide A, B | V‐ATPase | Preclinical | ( 26, 30 ) |
NS3736 | ClC‐7 Cl− channel | Preclinical | ( 32 ) |
KN‐93 | CaMKIV | Preclinical | ( 33 ) |
LFM‐A13 | Btk/Tec | Preclinical | ( 34 ) |
(‐)‐DHMEQ, PDTC | NF‐κB | Preclinical | ( 35, 36 ) |
Reveromycin A | IleRS | Preclinical | ( 43, 44 ) |
CaMKIV, Ca2+/calmodulin‐dependent kinase IV; (‐)‐DHMEQ, (‐)‐dehydroxymethylepoxyquinomicin; FPP, farnesyl pyrophosphate; IleRS, isoleucyl‐tRNA synthetase; PDTC, pyrrolidine dithiocarbamate.